A2 Milk share price: UBS maintains buy rating heading into H1 results
UBS analysts remain bullish on a2 Milk’s prospects as we approach the IMF company’s half-year results.
A2 Milk share price at a glance
It’s been a good week for a2 Milk (ASX: A2M) shareholders. In the last five sessions the A2M share price has risen a shade over 5%, closing out the week at $15.50 per share.
All up, this has proven to be quite a reversal of fortunes for the company; last November the stock hit a low of $11.31 per share.
Past price volatility aside, the investment bank UBS has today taken the chance to reiterate their 'buy' rating on a2 Milk. UBS has also retained their previously set share price target of NZ$17.00 per share.
The company is expected to release their first-half results on February 27.
Do you own a2 Milk shares? You can hedge your downside risk by trading CFDs now.
UBS: the new and old view
Recent data compiled by UBS looks to have reaffirmed the broker's already bullish stance on the IMF company.
Here it was noted that:
‘A2 Platinum share of best sellers was up ~570bp [...] year-on-year over 2QFY20 and pricing was ~steady, plus competitive behaviours should support CBEC share [and] Port export data: points to 1H20 volume growth of ~26% vs. UBSe +23% y/y, assuming steady h/h inventory.’
This is not to say questions around A2’s growth prospects don’t remain, with UBS analysts pondering three central questions that are likely to impact the company moving forward. Centrally, these questions are:
'What is a realistic long-term share of the China IMF market' for A2?, 'what level of profitability can A2M retain to achieve share aspirations'?, and ‘does CEO turnover suggest risk to the strategy?'.
In saying that, A2's long-term growth profile is a favourable one – according to UBS. Revenue and earnings are expected to grow significantly in the coming years, while margins are expected to remain stable.
Looking at the specifics, UBS posits that A2’s revenue will rise from NZ$1,670.2m in FY20e to NZ$2,732.3m in FY23e. Earnings are expected to climb in-step, with net earnings forecast to come in at NZ$346.5m in FY20e and NZ$579.7m in FY23e.
Earnings (EBIT) margins are also expected to remain stable over the coming years, according to UBS, currently expected to hit 29.5% in FY20e, 29.2% in FY21e, 28.7% in FY22e and 29.7% in FY23e.
Though UBS may be positive on A2M's outlook, this is not a view held by all brokers.
For example and at the other end of the spectrum, Citi analysts ultimately believe that over the medium-term A2M's margins will contract as Chinese IMF competition increases and as a 'shift to direct channels' occurs.
In saying that, Citi has moderated their bearish stance in recent times: just this week upgrading their rating from ‘sell’ to ‘neutral’ and upgrading their 12-month share price target from $12.30 to $14.85 on a2 Milk.
Ready to start hedging? Open an account with IG today to get started.
IGA, may distribute information/research produced by its respective foreign affiliates within the IG Group of companies pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the research is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, IGA accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact IGA at 6390 5118 for matters arising from, or in connection with the information distributed.
The information/research herein is prepared by IG Asia Pte Ltd (IGA) and its foreign affiliated companies (collectively known as the IG Group) and is intended for general circulation only. It does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. You should take into account your specific investment objectives, financial situation, and particular needs before making a commitment to trade, including seeking advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit.
No representation or warranty is given as to the accuracy or completeness of this information. Consequently, any person acting on it does so entirely at their own risk. Please see important Research Disclaimer.
Please also note that the information does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. Any views and opinions expressed may be changed without an update.
Seize a share opportunity today
Go long or short on thousands of international stocks.
- Increase your market exposure with leverage
- Get spreads from just 0.1% on major global shares
- Trade CFDs straight into order books with direct market access
Live prices on most popular markets
- Forex
- Shares
- Indices
See more forex live prices
See more shares live prices
Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.
See more indices live prices
Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 20 mins.